Company

Zephyr AI, Inc.

Zephyr AI analyzes healthcare data to support drug development and precision treatment.

About

Zephyr AI uses data and algorithms to support drug development, drug repurposing, clinical trial design, precision treatment recommendations, and disease prevention. Founded in 2020 and based in Virginia, US, it raised USD 111 million in series A funding in March 2024 from EPIQ Capital Group, Eli Lilly & Company Foundation, and Revolution Ventures. The round valued the company at USD 387.08 million post-money.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in